Pharmaceuticals

Hyqvia Market 2026 expanding with immune deficiency treatment demand

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Hyqvia Market At The End Of The 2026–2030 Forecast Period?

The expansion observed over the historic period can be attributed to the inherent limitations of intravenous IG therapy, the elevated infection susceptibility among PI patients, the swift adoption of SC immunoglobulins, the imperative for an enhanced quality of life, and the expansion within immunology specialty care.

Future growth is expected to be fueled by an increase in primary immunodeficiency diagnoses, the expansion of home healthcare services, improved management of pediatric primary immunodeficiency cases, a growing preference for less frequent dosing intervals, and the expanding distribution networks of specialty pharmacies. Key trends identified for this period involve a move towards less frequent immunoglobulin infusions, a greater adoption of home-based infusion therapies, a heightened demand for combination immunotherapy products, enhanced patient convenience in primary immunodeficiency treatment, and the broader use of subcutaneous immunoglobulin.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20092&type=smp

What Drivers Are Shaping The Future Growth Of The Hyqvia Market?

The increasing occurrence of autoimmune conditions is anticipated to fuel the expansion of the hyqvia market moving ahead. These diseases are characterized by the immune system erroneously targeting healthy cells, tissues, or organs, resulting in inflammation and impaired function. Their increase stems from multiple elements such as genetic susceptibility, environmental irritants, dietary shifts, greater exposure to contaminants, and enhanced diagnostic tools. Hyqvia addresses autoimmune diseases by providing immunoglobulin therapy, assisting in immune system modulation and reducing irregular immune responses directed at the body’s own tissues. As an illustration, in May 2023, the NIHR Imperial Biomedical Research Centre, a UK-based government research body, reported a study that reviewed anonymized electronic health records of 22 million UK individuals to investigate 19 prevalent autoimmune diseases, impacting approximately 10% of the population, specifically 13% of women and 7% of men. Consequently, the rising incidence of autoimmune diseases is propelling the growth of the hyqvia market.

What Segment Types Make Up The Hyqvia Market?

The hyqvia market covered in this report is segmented –

1) By Patient Demographics: Pediatric Patients, Adult Patients

2) By Distribution Channel: Hospitals, Specialty Pharmacies, Home Healthcare Providers, Retail Pharmacies

3) By Application: Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy, Other Applications

Which Market Trends Are Creating New Opportunities In The Hyqvia Market?

A significant trend in the hyqvia market is the concentration on developing innovative products, such as immune globulin infusion, aimed at treating chronic inflammatory demyelinating polyneuropathy (CIDP) and primary immunodeficiency (PI). Immune globulin infusion serves as a treatment method involving the administration of antibody-rich plasma proteins to address both immune deficiencies and autoimmune disorders. For instance, in January 2024, Takeda Pharmaceutical Company Ltd., a Japan-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted approval for its product, HYQVIA® (immune globulin infusion 10% [human] with recombinant human hyaluronidase), to be used as a maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This FDA approval authorizes HYQVIA for preventing relapses of neuromuscular disability and impairment caused by CIDP, a rare neuromuscular disorder that affects approximately five to seven individuals per 100,000 in the U.S.

Who Are The Key Players Driving Competition In The Hyqvia Market?

Major companies operating in the hyqvia market are Takeda Pharmaceutical Company Limited

Read the full hyqvia market report here:

https://www.thebusinessresearchcompany.com/report/hyqvia-global-market-report

Which Geographic Regions Are Influencing Demand In The Hyqvia Market?

North America was the largest region in the hyqvia market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the hyqvia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Hyqvia Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20092&type=smp

Browse Through More Reports Similar to the Global Hyqvia Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Hypermarkets Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypermarkets-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795